BYK324677

BYK324677 is a small molecule phosphodiesterase 4 (PDE4) inhibitor that was developed by Nycomed (now part of Takeda) for the treatment of inflammatory respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. PDE4 is an enzyme that breaks down cyclic adenosine monophosphate (cAMP) in inflammatory cells; by inhibiting this enzyme, BYK324677 increases intracellular cAMP levels, leading to the suppression of various inflammatory mediators and the relaxation of airway smooth muscle. The compound underwent Phase 1 clinical evaluation in healthy volunteers to assess its safety, tolerability, and pharmacokinetics, including the effects of sex and food on its profile. However, development appears to have been discontinued as no recent clinical activity has been reported since the completion of early-phase trials in 2008.

Other names

BYK324677BYK-324677BYK 324677